Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206

References

• Jost P, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, DOI 10.1182/blood-2006-07-025809
   PubMed Web of Science ®Google Scholar
• Bargou R C, Leng C, Krappmann D, Emmerich F, Mapara M Y, Bommert K, Royer H D, Scheidereit C, Dorken B. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed – Sternberg cells. Blood 1996; 87: 4340–4347
   PubMed Web of Science ®Google Scholar
• Krappmann D, Emmerich F, Kordes U, Sherschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed – Sternberg cells. Oncogene 1999; 18: 943–953
   PubMed Web of Science ®Google Scholar
• Staudt L M. The molecular and cellular origins of Hodgkin's disease. J Exper Med 2000; 191: 207–212
   PubMed Web of Science ®Google Scholar
• Heckman C, Mehew J, Boxer L. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002; 21: 3898–3908
   PubMed Web of Science ®Google Scholar
• Ho L, Davis R E, Conne B, Chappuis R, Berczy M, Mhauech P, Staudt L M, Schwaller J. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-{κ}B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005; 105: 2891–2899
   PubMed Web of Science ®Google Scholar
• Davis R, Brown K, Siebenlist U, Staudt L. Constitutive nuclear factor κB activity is required for survival of activated B-cell like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–1874
   PubMed Web of Science ®Google Scholar
• Emmerich F, Meiser M, Hummel M, Demel G, Foss H D, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dorken B. Overexpression of I κBα without inhibition of NF-κB activity and mutations in the I κBα gene in Reed – Sternberg cells. Blood 1999; 94: 3219–3134
   Google Scholar
• Horie R, Watanabe T, Morishita Y, Ho K, Ishida Y, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin M E, Watanabe T. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin – Reed – Sternberg cells. Oncogene 2002; 21: 2493–2503
   PubMed Web of Science ®Google Scholar
• Fiumara P, Snell V, Li V, Mukhopadhyay A, Younes M, Gillenwater A M, Cabanilles F, Aggarwal B B, Younes A. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 2001; 98: 2784–2790
   PubMed Web of Science ®Google Scholar
• Darnay B, Haridas V, Ni J, Moore P, Aggarwal B. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1998; 273: 20551–20555
   PubMed Web of Science ®Google Scholar
• Grech A, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 2004; 21: 629–642
   PubMed Web of Science ®Google Scholar
• Eliopoulos A, Caamano J, Flavell J, Reynods G M, Murray P G, Poyet J L, Young L S. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-κB2 to p52 via an IKK γ/NEMO-independent signaling pathway. Oncogene 2003; 22: 7557–7569
   PubMed Web of Science ®Google Scholar
• Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Sheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed – Sternberg cells. Blood 2001; 97: 2798–2807
   PubMed Web of Science ®Google Scholar
• Izban K F, Ergin M, Huang Q, Qin J Z, Martinez R L, Schnitzer B, Ni H, Nickoloff B J, Alkan S. Characterization of NF-κB expression in Hodgkin's disease: inhibition of constitutively expressed NF-κB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed – Sternberg cells. Modern Pathol 2001; 14: 297–310
   PubMed Web of Science ®Google Scholar
• Zheng B, Georgakis G, Li Y, Bhart A, McConkey D, Aggarwal B B, Younes A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin Disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207–3215
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, Niesvizky R, Alexanian R, Limentani S A, Alsina M, Adams J, Kauffman M, Esseltine D L, Schenkein O P, Anderson K C. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagganath S, Irwin D, Roykumar S V, Srkalovic J, Alsina M, Alexanian R, Siegel D, Orlowski R Z, Kuter D, Limentani S A, Lee S, Hideshima T, Esseltine D-L, Kaufmann M, Adams J, Shenkein D P, Anderson K C. A Phase 2 Study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguerra J E, Hagemeister F, Fayad L, Dang N H, Samaniego F, Wang M, Broglio K, Samuels B, Giles F, Sarris A G, Hart S, Trehu S, Schenkein D, Cabanillas F, Rodriguez A M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu B, Esseltine D, Trehu E, Adams J, Schenkein D, Zelentz A. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
   PubMed Web of Science ®Google Scholar
• Fisher R I, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, de Vos S, Epner E, Krishnan A, Leonard J P, Lonial S, Stadtmauer E A, O'Connor O A, Shi H, Boral A L, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, Lister T A, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris N L, Armitage J O, Carter W, Hoppe R, Canellos G P. Report of an international report to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Santor A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra H S, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2619
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5: 817–820
   PubMed Web of Science ®Google Scholar
• Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006; 107: 1731–1732
   PubMed Web of Science ®Google Scholar
• Cabannes E, Khan G, Aillet F, Jarrett R, Hay R. Mutations in IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα. Oncogene 1999; 18: 3063–3070
   PubMed Web of Science ®Google Scholar
• Emmerich F, Theurich S, Hummel M, Haeffker A, Vry M S, Dohner K, Bommert K, Stein H, Dorken B. Inactivating IκB epsilon mutations in Hodgkin Reed – Sternberg cells. J Pathol 2003; 201: 413–420
   PubMed Web of Science ®Google Scholar
• Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V, Hansmann M L, Rajewskly K, Kuppers R. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395–402
   PubMed Web of Science ®Google Scholar
• Joos S, Menz C, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtersheimer G, Trumper L, Moller P, Lichter P, Barth T F. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99: 1381–1387
   PubMed Web of Science ®Google Scholar
• Martin-Subero J, Gesk S, Harder L, Sonoki T, Tucker P W, Schlegelberger B, Grote W, Novo F J, Calasanz M J, Hansmann M L, Dyer M J, Seibert R. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99: 1474–1477
   PubMed Web of Science ®Google Scholar
• Barth T, Martin-Subero J, Joos S, Menz C K, Hasel C, Mechtersheimer G, Parwaresch R M, Lichter P, Siebert R, Mooler P. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 2003; 101: 3681–3686
   PubMed Web of Science ®Google Scholar
• Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, von Strandmann E P. The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106: 1839–1842
   PubMed Web of Science ®Google Scholar
• Kashkar H, Deggerich A, Seeger J-M, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Kronke M. NF-κB independent down-regulation of XIAP by bortezomib sensitizes HL B-cells against cytotoxic drugs. Blood 2007; 109: 3982–3988
   PubMed Web of Science ®Google Scholar
• Sterz J, Jakob C, Kuckelkorn U, Braun H A, Kaiser M, Fleissner C, Kleeberg L, Heider U, Possinger K, Kloetzel P M, Sezer O, Zavrski I. BSc2118, a novel proteasome inhibitor, shows anti-tumor activity in multiple myeloma and mantle cell lymphoma. Blood 2006; 108(Suppl): 3475
   Google Scholar
• O'Connor O A, Orlowski R Z, Alsina M, Steward K, Trudel S, Wallone M K, Woo T M, Urquilla P R, Molineaux C J, Goy A. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematologic malignancies. Blood 2006; 108(Suppl): 2430
   Google Scholar